InsiderTrades

Form 4 for AVTX Avalo Therapeutics, Inc.

Accepted 2023-02-09 00:00:00 ET · period of report 2023-02-03 · accession 0000899243-23-004412 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DI 2023-02-09 2023-02-03 AVTX ARMISTICE CAPITAL, LLC 10% L - Small Acq $3.95 +334 3.96M +0.0% +$1,319
DI 2023-02-09 2023-02-07 AVTX ARMISTICE CAPITAL, LLC 10% P - Purchase — +450.0K 4.42M +11% —
DI 2023-02-09 2023-02-07 AVTX ARMISTICE CAPITAL, LLC 10% P - Purchase — +450.0K 450.0K New —

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2023-02-03 L A 334 $3.95 3,965,000 I See Footnote — — (F1) This amount reflects the effect of the 1-for-12 reverse stock split. (F2) The reported securities of Avalo Therapeutics, Inc. (the "Issuer") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the "Master Fund"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC ("Armistice Capital"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital ("Mr. Boyd", and collectively with the Master Fund and Armistice Capital, the "Reporting Persons"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
2 Common Common Stock 2023-02-07 P A 450,000 — 4,415,000 I See Footnote — — (F3) Each share of common stock and accompanying warrant were purchased together for $3.98. The warrants are subject to a 4.99% beneficial ownership limitation on exercise. (F1) This amount reflects the effect of the 1-for-12 reverse stock split. (F2) The reported securities of Avalo Therapeutics, Inc. (the "Issuer") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the "Master Fund"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC ("Armistice Capital"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital ("Mr. Boyd", and collectively with the Master Fund and Armistice Capital, the "Reporting Persons"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
3 Derivative Warrant 2023-02-07 P A 450,000 — 450,000 I See Footnote $5.00 · 2023-02-07 to 2024-02-07 450,000 Common Stock (F4) These shares are directly owned by Mr. Boyd in his personal capacity. (F1) This amount reflects the effect of the 1-for-12 reverse stock split. (F2) The reported securities of Avalo Therapeutics, Inc. (the "Issuer") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the "Master Fund"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC ("Armistice Capital"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital ("Mr. Boyd", and collectively with the Master Fund and Armistice Capital, the "Reporting Persons"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.